{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:03:52Z","timestamp":1794027832820,"version":"4.8.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.esmoop.2025.105922","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T16:58:04Z","timestamp":1764694684000},"page":"105922","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial"],"prefix":"10.1016","volume":"10","author":[{"given":"J.","family":"Capdevila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tafuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2410-9559","authenticated-orcid":false,"given":"M.","family":"Krogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0028-7200","authenticated-orcid":false,"given":"A.","family":"Teul\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-397X","authenticated-orcid":false,"given":"R.","family":"Garcia-Carbonero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7290-1823","authenticated-orcid":false,"given":"H.-J.","family":"Kl\u00fcmpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Cremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Sevilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tabaksblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-P.","family":"Metges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.S.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Schrader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6157-8661","authenticated-orcid":false,"given":"V.","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2963-7713","authenticated-orcid":false,"given":"V.","family":"Valent\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Vestermark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Carnaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.P.","family":"Knigge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4592-3813","authenticated-orcid":false,"given":"P.","family":"Jimenez-Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1268-4588","authenticated-orcid":false,"given":"M.","family":"Benavent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2578-1766","authenticated-orcid":false,"given":"J.","family":"de Vos-Geelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8581-0974","authenticated-orcid":false,"given":"M.","family":"Venerito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Von Werder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Jann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8156-2915","authenticated-orcid":false,"given":"A.","family":"Rinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"H\u00f6rsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Starling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ruszniewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2198-3582","authenticated-orcid":false,"given":"E.","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.-X.","family":"Caroli-Bosc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8987-4577","authenticated-orcid":false,"given":"J.L.","family":"Manzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1678-739X","authenticated-orcid":false,"given":"A.","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.T.","family":"Lawlor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9520-4844","authenticated-orcid":false,"given":"C.","family":"Ragulan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sadanandam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Carmona-Bayonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9419-6232","authenticated-orcid":false,"given":"R.","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.esmoop.2025.105922_bib1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/oncolo\/oyac049","article-title":"Survival and incidence patterns of pancreatic neuroendocrine tumors over the last 2 decades: a SEER database analysis","volume":"27","author":"Sonbol","year":"2022","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105922_bib2","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105922_bib3","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13318","article-title":"European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes","volume":"35","author":"Hofland","year":"2023","journal-title":"J Neuroendocrinol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105922_bib4","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13343","article-title":"European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours","volume":"35","author":"Kos-Kud\u0142a","year":"2023","journal-title":"J Neuroendocrinol"},{"issue":"28","key":"10.1016\/j.esmoop.2025.105922_bib5","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105922_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000443612","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival","volume":"104","author":"Rinke","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105922_bib7","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105922_bib8","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.esmoop.2025.105922_bib9","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1200\/JCO.2016.68.0702","article-title":"Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study","volume":"34","author":"Yao","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105922_bib10","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.esmoop.2025.105922_bib11","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1200\/JCO.2004.04.024","article-title":"Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas","volume":"22","author":"Kouvaraki","year":"2004","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105922_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143822","article-title":"Streptozocin-based chemotherapy in patients with advanced neuroendocrine neoplasms \u2013 predictive and prognostic markers for treatment stratification","volume":"10","author":"Krug","year":"2015","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105922_bib13","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.ejca.2015.04.005","article-title":"Streptozocin\/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours","volume":"51","author":"Dilz","year":"2015","journal-title":"Eur J Cancer"},{"issue":"3-4","key":"10.1016\/j.esmoop.2025.105922_bib14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000439086","article-title":"Streptozocin and 5-fluorouracil for the treatment of pancreatic neuroendocrine tumors: efficacy, prognostic factors and toxicity","volume":"103","author":"Clewemar Antonodimitrakis","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105922_bib15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12020-021-02859-y","article-title":"Streptozocin\/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy","volume":"75","author":"Lahner","year":"2022","journal-title":"Endocrine"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105922_bib16","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)","volume":"41","author":"Kunz","year":"2023","journal-title":"J Clin Oncol. Oncol"},{"issue":"suppl 7","key":"10.1016\/j.esmoop.2025.105922_bib17","article-title":"887O First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: results of the OCLURANDOM trial","volume":"33","author":"Baudin","year":"2022","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105922_bib18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.esmoop.2025.105922_bib19","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.105922_bib20","volume":"37","year":"2025","journal-title":"J Neuroendocrinol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2025.105922_bib21","article-title":"Pivotal phase III COMPOSE trial will compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Halfdanarson","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105922_bib22","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eprac.2021.08.008","article-title":"Sequential capecitabine\/temozolomide and sunitinib treatment in patients with metastatic well-differentiated grade 1\/grade 2 pancreatic neuroendocrine tumors","volume":"28","author":"Gao","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.esmoop.2025.105922_bib23","author":"Gustave"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105922_bib24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2307\/2529990","article-title":"A simple approximation for calculating sample sizes for comparing independent proportions","volume":"36","author":"Fleiss","year":"1980","journal-title":"Biometrics"},{"key":"10.1016\/j.esmoop.2025.105922_bib25","series-title":"R (version 3.6.3 [2020-02-29]","year":"2020"},{"key":"10.1016\/j.esmoop.2025.105922_bib26","unstructured":"SPSS Version 26. IBM SPSS Statistics. Armonk, NY, USA."},{"issue":"9","key":"10.1016\/j.esmoop.2025.105922_bib27","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1634\/theoncologist.2014-0037","article-title":"Real-world study of everolimus in advanced progressive neuroendocrine tumors","volume":"19","author":"Panzuto","year":"2014","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105922_bib28","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1210\/jc.2011-2088","article-title":"Clinical review: current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy","volume":"97","author":"Bousquet","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.esmoop.2025.105922_bib29","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2147\/OTT.S36330","article-title":"Prognostic significance of AKT\/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs","volume":"5","author":"Fernandes","year":"2012","journal-title":"Onco Targets Ther"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105922_bib30","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000111501","article-title":"Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line","volume":"87","author":"Grozinsky-Glasberg","year":"2008","journal-title":"Neuroendocrinology"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105922_bib31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/cells14040245","article-title":"\u201cCold\u201d somatostatin analogs in neuroendocrine neoplasms: decoding mechanisms, overcoming resistance, and shaping the future of therapy","volume":"14","author":"Massironi","year":"2025","journal-title":"Cells"},{"issue":"21","key":"10.1016\/j.esmoop.2025.105922_bib32","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM198011203032101","article-title":"Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma","volume":"303","author":"Moertel","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2025.105922_bib33","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/s12885-015-1512-6","article-title":"Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis","volume":"15","author":"Capdevila","year":"2015","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105922_bib34","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM199202203260804","article-title":"Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma","volume":"326","author":"Moertel","year":"1992","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105922_bib35","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa2403991","article-title":"Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors","volume":"392","author":"Chan","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105922_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102386","article-title":"Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors","volume":"9","author":"Al-Toubah","year":"2024","journal-title":"ESMO Open"},{"issue":"20","key":"10.1016\/j.esmoop.2025.105922_bib37","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1200\/JCO.20.03368","article-title":"Lenvatinib in patients with advanced grade 1\/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase II TALENT trial (GETNE1509)","volume":"39","author":"Capdevila","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105922_bib38","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","article-title":"Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10446","key":"10.1016\/j.esmoop.2025.105922_bib39","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105922_bib40","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.3390\/jcm14072384","article-title":"Evaluation of the real-life efficacy and safety of the treatment with lutetium-177 dotatate for metastatic neuroendocrine tumors","volume":"14","author":"Campos Ram\u00edrez","year":"2025","journal-title":"J Clin Med"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2025.105922_bib41","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1200\/JCO.2025.43.4_suppl.652","article-title":"A phase III study of combination therapy with everolimus plus lanreotide versus everolimus monotherapy for unresectable or recurrent gastroenteropancreatic neuroendocrine tumor (JCOG1901, STARTER-NET)","volume":"43","author":"Hijioka","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:21:43Z","timestamp":1773865303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925017922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2059702925017922"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105922","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105922","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105922"}}